Atria Wealth Solutions Inc. Has $511,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Atria Wealth Solutions Inc. decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,162 shares of the medical research company’s stock after selling 105 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Charles River Laboratories International were worth $511,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Commonwealth Equity Services LLC increased its position in Charles River Laboratories International by 9.4% during the third quarter. Commonwealth Equity Services LLC now owns 30,720 shares of the medical research company’s stock worth $6,021,000 after buying an additional 2,643 shares during the last quarter. Xponance Inc. raised its stake in shares of Charles River Laboratories International by 4.7% in the 3rd quarter. Xponance Inc. now owns 7,389 shares of the medical research company’s stock valued at $1,448,000 after acquiring an additional 335 shares in the last quarter. Stratos Wealth Partners LTD. raised its stake in shares of Charles River Laboratories International by 24.5% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 2,505 shares of the medical research company’s stock valued at $491,000 after acquiring an additional 493 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Charles River Laboratories International by 1.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 412,453 shares of the medical research company’s stock worth $80,833,000 after purchasing an additional 7,590 shares during the last quarter. Finally, Brown Advisory Inc. boosted its position in Charles River Laboratories International by 0.8% during the third quarter. Brown Advisory Inc. now owns 14,913 shares of the medical research company’s stock worth $2,923,000 after purchasing an additional 117 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 1.6 %

Shares of CRL stock opened at $233.47 on Monday. The stock has a market cap of $12.03 billion, a P/E ratio of 25.35, a price-to-earnings-growth ratio of 1.83 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The stock has a fifty day moving average price of $252.23 and a 200 day moving average price of $224.20. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same period in the previous year, the business earned $2.98 EPS. The firm’s revenue was down 7.9% on a year-over-year basis. Analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Activity

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,932 shares of company stock worth $3,693,663. Company insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on CRL. Argus upped their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. UBS Group upped their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Citigroup increased their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Finally, TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).